Ego Pharmaceuticals, a venerable Australian pharmaceutical company, has made remarkable strides in its analytical laboratory by embracing automation. This transformative journey showcases how innovation can break through the entrenched mindset of “we’ve always done it this way,” leading to significant operational improvements.
By implementing automated processes, Ego Pharmaceuticals achieved a staggering reduction of up to 92% in hands-on analyst time for critical assays. Additionally, solvent consumption decreased by 58%, while the accuracy of UV/Vis measurements surpassed the reliability of traditional manual techniques. This shift not only enhanced lab efficiency but also fostered a commitment to green chemistry and continuous innovation, earning the company national acclaim.
The Evolution of Ego Pharmaceuticals
Founded in 1953 in Melbourne, Ego Pharmaceuticals has grown from a modest compounding laboratory to a leading producer of dermatological and skincare products in Australia. The company’s reputation is built on a foundation of high-quality, pharmaceutical-grade ingredients, such as glycerin and petroleum jelly, which require meticulous analytical assessments to ensure compliance with regulatory standards.
Ego’s Quality Control (QC) laboratory is responsible for a broad spectrum of compendial assessments, including pH, viscosity, density, and various chromatographic techniques. Analysts are tasked with maintaining high throughput while safeguarding data integrity in line with British, European, and United States Pharmacopeia standards, presenting a constant challenge.
At the heart of this innovation is Ego’s Analytical Development Team, which questioned the status quo by asking why processes that seemingly functioned well could not be further optimized.
Embracing Change: A Commitment to Innovation
Ego’s automation initiative was driven by a strong desire for continuous improvement expressed by its employees. They sought more streamlined workflows, enhanced collaboration, and an organizational culture that welcomed process enhancements as a norm rather than an exception.
In parallel, the laboratory leadership laid out a strategic vision focusing on three key areas: becoming Cleaner by optimizing efficiency, Greener by advancing sustainability through the principles of green chemistry, and Future-Focused by fostering ongoing innovation and communication.
To bring this vision to life, the analytical team conducted a thorough evaluation of existing workflows. They identified bottlenecks and highlighted manual-intensive tasks, prioritizing multi-step processes where automation could yield significant benefits. Two primary areas emerged as candidates for automation: UV/Vis spectrophotometric assays and titration procedures for pharmaceutical ingredients.
UV/Vis Spectrophotometry: A Game-Changer
UV/Vis spectrophotometry is integral to quality control in the pharmaceutical industry, serving as a critical tool for validating the identity, potency, and purity of both active pharmaceutical ingredients and excipients.
Previously, Ego relied on manual workflows for these assays, which involved preparing sample solutions and standards by hand, performing solvent extractions, and transferring solutions into cuvettes or flow cells for analysis. Each step was prone to variability, complicating the process.
The biggest challenge in pharmaceutical UV/Vis testing lies in the sample preparation phase rather than the measurement itself, as modern instruments such as the METTLER TOLEDO UV7 are already highly precise. Techniques like liquid-liquid extraction require accurate volumetric additions, precise timing, and consistent mixing—factors that are difficult to standardize in a manual setting.
To tackle these challenges, Ego Pharmaceuticals integrated the METTLER TOLEDO UV7 spectrophotometer with the ePrep ONE Sample Preparation Workstation, creating a comprehensive, validated workflow. The ePrep ONE automates all liquid handling steps prior to measurement, including reagent preparation, volumetric additions, and timed extractions.
Once prepared, the UV instrument conducts measurements under controlled conditions, significantly reducing variability and ensuring that analytical results accurately reflect the quality of the methods employed.
Achieving Significant Returns on Investment
The first automated UV assay workflow introduced to the QC team at Ego demonstrated a compelling return on investment. It considerably reduced out-of-specification events and the need for rework across all applications transitioned to the new system.
The development of the UV/Vis automation program was further enriched through a collaboration with students from Monash University. These students, participating in an internship program, worked under the guidance of the Analytical Development team to develop and optimize methods. This initiative not only provided students with invaluable hands-on experience but also contributed to structured method development for Ego Pharmaceuticals.
The success of this program was recognized in late 2025 when Helen Evans-Lemmo, the program coordinator, received the Victorian Branch Industry Mentor of the Year Award from the Royal Australian Chemical Institute. This accolade honored the scientific quality and the meaningful industry placements provided to aspiring analytical chemists.
The Broader Impact of Automation
The results achieved by Ego Pharmaceuticals illustrate the profound impact of automation in enhancing laboratory efficiency and data integrity. The company’s commitment to continuous improvement, sustainability, and innovation positions it as a leader in the pharmaceutical industry.
By fostering a culture that embraces change and encourages collaboration, Ego has not only improved its internal processes but also contributed to the development of the next generation of analytical chemists.
Key Takeaways
- Ego Pharmaceuticals transformed its analytical lab by adopting automation, resulting in substantial efficiency gains.
- The integration of the METTLER TOLEDO UV7 and ePrep ONE Workstation streamlined workflows and enhanced data accuracy.
- Collaborations with educational institutions fostered talent development while benefiting the company’s operational processes.
In conclusion, Ego Pharmaceuticals exemplifies how embracing innovation and automation can lead to remarkable improvements in efficiency and quality. By challenging traditional practices and investing in future-focused strategies, the company has set a benchmark for excellence in the pharmaceutical sector. The journey underscores the potential for continuous improvement and the importance of a culture that supports change.
Read more → www.news-medical.net